ArticleMalaria journal2026
Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIndoor residual spraying (IRS) of insecticides is widely used as an effective method to control malaria vector mosquitoes in sub-Saharan Africa. In 2023, a new IRS product, VECTRON™ T500 (Mitsui Chemicals Crop & Life Solutions, Inc.), was launched. This product contains broflanilide, a novel active ingredient for IRS, and has been confirmed to exhibit long-lasting insecticidal efficacy against malaria vector mosquitoes. However, the discriminating concentration to assess the susceptibility of wild Anopheles populations to broflanilide has not yet been determined.
methodsIn this study, WHO bottle bioassays were conducted in nine research facilities to collect dose response data on broflanilide against adult female mosquitoes of the insecticide susceptible Anopheles gambiae s.s. Kisumu strain. These data were statistically analysed and validated following WHO guidelines.
resultsIt was determined that the preliminary discriminating concentration of broflanilide for An. gambiae mosquitoes should be 18 μg/bottle.
conclusionsIn this study, the preliminary discriminating concentration of broflanilide for An. gambiae mosquitoes was determined. The results of this study will provide a useful benchmark for susceptibility monitoring of wild mosquito populations in regions of sub-Saharan Africa into which VECTRON™ T500 is being introduced for malaria vector control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.